These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 16170178

  • 1. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
    Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL, Fung H, Krishnan A, Molina A, Nademanee A, O'Donnell M, Popplewell L, Rodriguez R, Forman SJ, Bhatia S.
    J Clin Oncol; 2005 Sep 20; 23(27):6699-711. PubMed ID: 16170178
    [Abstract] [Full Text] [Related]

  • 2. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L, Chiusolo P, Garzia MG, Zini G, Sorà F, Piccirillo N, Piccioni P, Zollino M, Leone G, Sica S.
    Haematologica; 2002 Jan 20; 87(1):59-66. PubMed ID: 11801466
    [Abstract] [Full Text] [Related]

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 20; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.
    Biol Blood Marrow Transplant; 2006 Jul 20; 12(7):703-11. PubMed ID: 16785059
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
    Sevilla J, Rodríguez A, Hernández-Maraver D, de Bustos G, Aguado J, Ojeda E, Arrieta R, Hernández-Navarro F.
    Ann Hematol; 2002 Jan 20; 81(1):11-5. PubMed ID: 11807629
    [Abstract] [Full Text] [Related]

  • 8. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM, Le Beau MM, Anastasi J, Williams SF.
    Bone Marrow Transplant; 1999 Jun 20; 23(11):1161-5. PubMed ID: 10382956
    [Abstract] [Full Text] [Related]

  • 9. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
    Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R.
    J Clin Oncol; 2009 Feb 10; 27(5):791-8. PubMed ID: 19124806
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
    Phillips GL, Meisenberg BR, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N.
    Bone Marrow Transplant; 2004 Apr 10; 33(8):781-7. PubMed ID: 14767498
    [Abstract] [Full Text] [Related]

  • 18. Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center.
    Molina A, Popplewell L, Kashyap A, Nademanee A.
    Clin Transpl; 2000 Apr 10; ():317-42. PubMed ID: 11512326
    [Abstract] [Full Text] [Related]

  • 19. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T.
    Bone Marrow Transplant; 2008 Apr 10; 41(7):613-9. PubMed ID: 18071290
    [Abstract] [Full Text] [Related]

  • 20. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim JE, Kim S, Lee DH, Lee JS, Park SJ, Park CJ, Huh J, Suh C.
    Transfusion; 2009 Sep 10; 49(9):1890-900. PubMed ID: 19453991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.